Spyre Therapeutics, Inc. SYRE Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s investment proceeds?
- Spyre Therapeutics, Inc. (SYRE) reported investment proceeds of $107.75M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s investment proceeds changed year-over-year?
- Spyre Therapeutics, Inc.'s investment proceeds increased by 50.9% year-over-year, from $71.38M to $107.75M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s investment proceeds?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s investment proceeds has grown at a 35.3% compound annual growth rate (CAGR), from $111.03M to $371.74M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.